



WE NEED YOU!

**Leveraging Neuropathologically Verified
Cases & Controls in the Genetic Study of AD**

Eric M. Reiman, M.D.

AD Genetics Consortium Neuropathology Work Group

Joe Buxbaum

Barbara Crain

Ramon Diaz-Arrastia

Tatiana Foroud (NCRAD)

Neill Graff-Radford

John Hardy

Walter Kukull (NACC)

Marylin Miller (NIA)

Marcelle Morrison-Bogorad (NIA)

Richard Mayeux

Amanda Myers

Tony Phelps (NIA)

Erin Ramos

Eric Reiman (Work Group Leader)

Jerry Schellenberg (Consortium Director)

Julie Schneider

Nina Silverberg (NIA)

Michael Slifer


Dietrich Stephan

Robin Walter

Jennifer Webster

Tom Wisjniewski

Entering the Era of Genome-Wide Association (GWA) Studies



Reiman et al, *Neuron* 2007

The Genetic Study of Neuropathologically Verified Cases & Controls

- Advantages
 - fewer misclassifications
 - quantitative endophenotypes
 - other neuropathological data
 - other neurobiological studies
- Disadvantages
 - availability of samples (especially controls)
 - availability & reliability of assessments
 - selection biases
- Complementary Role

APOE Genotype	Odds Ratio¹ Meta-analysis	Odds Ratio² Neuropathology
--------------------------	---	--

ε2ε2

0.6

0.4

ε2ε3

0.6

0.4

ε3ε3

1.0

1.0

ε2ε4

2.6

3.5

ε3ε4

3.2

4.3

ε4ε4

14.9

25.3

¹Farrer et al, *JAMA* 1997: Meta-analysis of 14,537 cases & controls

²Coon et al, *J Clin Psychiatry* 2007: 1,080 neuropathologically verified cases & controls

AD Genetics Consortium Neuropathology Work Group



To establish a central resource of DNA & data from neuropathologically verified late-onset AD cases & controls for GWA, replication & other genetic studies of late-onset AD

Our Immediate Need

Information & brain samples from up to 6,000 expired donors within the next few months!*



*Including as many controls as possible
& up to 4x the number of AD cases



Criteria for AD Cases

1. Clinical diagnosis of probable or possible AD
2. Minimum age at dementia onset: 50
3. If evaluated for AD using NIA-Reagan criteria:
Intermediate or high probability that AD accounts for dementia
4. If not evaluated using NIA-Reagan criteria:
 - a. Braak III-IV or V-VI and
 - b. moderate or frequent neocortical neuritic plaques (highest neocortical plaque density)

*Cases will be included whether or not they have comorbid neuropathology (e.g., infarcts)

Criteria for Controls

1. Clinical confirmation of non-dementia within 12 months of death
2. Minimum age at death: 50
3. If evaluated for AD using NIA-Reagan criteria:
Low probability that AD accounts for dementia
4. If not evaluated using NIA-Reagan criteria:
 - a. Braak 0-III and
 - b. No or sparse neocortical neuritic plaques (highest neocortical plaque density)

*Controls will be included whether or not they have comorbid neuropathology (e.g., infarcts)

We Need Your Help!

1. Send us information about your cases & controls ASAP
 - Find as many suitable cases & controls from your ADC & affiliated brain banks
 - Also inform us of controls who meet other criteria but who were not clinically confirmed to be dementia-free or have not yet had complete neuropathological assessment
 - Compare your numbers to those NACC sends to you next week
2. Ship requested frozen brain samples to NCRAD ASAP
 - 3-5 g from the frontal pole is strongly preferred, but as little as 1 g from any region (e.g., cerebellum) would be acceptable
 - Please send samples even if you did so before
 - Send data & invoice to NACC (per Bud)
 - LOAD MDS & Neuropath forms for non-NACC samples
3. Provide additional information (TBD) later



Overcoming the Paucity of Control Samples

1. Let us know about affiliated & non-affiliated brain banks with controls (& cases) who meet our criteria
2. Inform us about additional controls who are thought to be non-demented, meet other control criteria, but were not evaluated in the last 12 months before death
3. Inform us about potential controls who have not had complete neuropathological assessment
4. Consider (at a later time) donors with Braak ratings irrespective of their clinical diagnosis
5. Other suggestions?

What We Can Do For You

1. \$50 per brain sample
2. On-site sample help (if wanted)
3. Virtually unlimited supply of extracted DNA
 - Delegate DNA storage & distribution to NCRAD
 - Return up to 100 μg of DNA to interested sites (depending on amount of tissue provided)
4. APOE genotypes
5. Meeting the NIH/NIA/ADC sample & data sharing requirement
6. The science itself

Lending a Hand



What We Can Do For You

1. \$50 per brain sample
2. On-site sampling help (if wanted)
3. Virtually unlimited supply of extracted DNA
 - Delegate DNA storage & distribution to NCRAD
 - Return up to 100 μg of DNA to interested sites (depending on amount of tissue provided)
4. APOE genotypes
5. Meeting the NIH/NIA/ADC sample & data sharing requirement
6. The science itself

Lending a Hand



And How Did the Neuropathology Core Leaders Respond?





Acknowledgements



- NIA, NACC, NCRAD & (hopefully) FNIH
- Tony Phelps, Marilyn Miller & Marcelle Morrison-Bogorad
- Bud Kukull, Tatiana Foroud & Amanda Myers
- AD Genetics Consortium & Neuropathology Work Group
- You!

THANK YOU!

